Current Research

A major aspect of its research program is the development of humanised mouse models using patient samples, normal cord blood or bone marrow-derived stem cells and recently engineered, improved recipient mouse strains to model systemic disease. We apply integrated omics profiling and single cell sequencing in combination with CRISPR/Cas9-mediated gene editing to characterise the molecular responses to standard and novel therapies. Specifically, the lab investigates the role of lipid desaturation and ferroptosis in leukaemic stem and immune cell compartments, and aims to identify metabolic vulnerabilities that can be exploited to develop novel, effective therapies for AML.